Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Repare Therapeutics Inc (RPTX)
NASDAQ:RPTX
Repare Therapeutics (RPTX) Stock Price & Analysis
259 Followers
RPTX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.00 - $13.85
Previous Close$3.02
Volume140.29K
Average Volume (3M)129.10K
Market Cap
$127.39M
Enterprise Value-$92.83M
Total Cash (Recent Filing)$223.63M
Total Debt (Recent Filing)$3.41M
Price to Earnings (P/E)-1.4
Beta0.97
Next Earnings
May 08, 2024EPS Estimate
$0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.23
Shares Outstanding42,182,177
10 Day Avg. Volume92,135
30 Day Avg. Volume129,097
Standard Deviation0.21
R-Squared0.02
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.66
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.83
Forecast
1Y Price Target
$16.60Price Target Upside449.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Repare Therapeutics News
PremiumCompany Announcements
Repare Therapeutics Reports Promising 2023 Progress
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentPromising clinical data in advanced tumors for key product candidates like lunresertib and camonsertib has been observed.
Financial PerformanceRepare recorded a net diluted loss of $2.23 per share, narrower than the prior estimate of a net loss of $2.44 per share, due to higher than anticipated collaboration revenue.
Licensing And PartnershipsPotential options for camonsertib's development could enhance its value, including out-licensing to a major pharmaceutical firm or continuing its development in various combinations.
Bears Say
Drug DevelopmentDespite early efficacy, there is investor concern about high anemia rates in the combination arm of the study.
Financial PerformanceA projected full-year 2024 net loss of $2.87 per share indicates ongoing financial challenges for Repare.
Strategic PartnershipsRoche has decided to terminate its worldwide license and collaboration agreement for camonsertib.
---
Ownership Overview
77.59% Insiders
3.91% Mutual Funds
14.03% Other Institutional Investors
4.47% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RPTX FAQ
What was Repare Therapeutics Inc’s price range in the past 12 months?
Repare Therapeutics Inc lowest stock price was $3.00 and its highest was $13.85 in the past 12 months.
What is Repare Therapeutics Inc’s market cap?
Currently, no data Available
When is Repare Therapeutics Inc’s upcoming earnings report date?
Repare Therapeutics Inc’s upcoming earnings report date is May 08, 2024 which is in 19 days.
How were Repare Therapeutics Inc’s earnings last quarter?
Repare Therapeutics Inc released its earnings results on Feb 28, 2024. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.359 by -$0.311.
Is Repare Therapeutics Inc overvalued?
According to Wall Street analysts Repare Therapeutics Inc’s price is currently Undervalued.
Does Repare Therapeutics Inc pay dividends?
Repare Therapeutics Inc does not currently pay dividends.
What is Repare Therapeutics Inc’s EPS estimate?
Repare Therapeutics Inc’s EPS estimate is $0.02.
How many shares outstanding does Repare Therapeutics Inc have?
Repare Therapeutics Inc has 42,182,180 shares outstanding.
What happened to Repare Therapeutics Inc’s price movement after its last earnings report?
Repare Therapeutics Inc reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.359. Following the earnings report the stock price went down -0.901%.
Which hedge fund is a major shareholder of Repare Therapeutics Inc?
Among the largest hedge funds holding Repare Therapeutics Inc’s share is ARK Investment Management LLC. It holds Repare Therapeutics Inc’s shares valued at 21M.
---
Repare Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.60 (449.67% Upside)
$16.60 (449.67% Upside)
Blogger Sentiment
Bullish
RPTX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 200.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 2.1%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.21%
12-Months-Change
Fundamentals
Return on Equity
-38.16%
Trailing 12-Months
Asset Growth
-30.26%
Trailing 12-Months
Company Description
Repare Therapeutics Inc
Repare Therapeutics Inc is a precision oncology company engaged in discovery and development of novel therapeutics. The company use its proprietary, genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Using its SNIPRx platform, it is developing pipeline of SL product candidates, including its product candidate, RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations.
---
RPTX Stock 12 Months Forecast
Average Price Target
$16.60
▲(449.67% Upside)
Technical Analysis
Best Analysts Covering RPTX
1 Year
1 Year Success Rate
1/12 ratings generated profit
1 Year Average Return
-40.81%
assigned a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 8.33% of your transactions generating a profit, with an average return of -40.81% per trade.
---